

DIPARTIMENT TAS-SAĦĦA



DEPARTMENT OF HEALTH

*Direttorat Għas-Servizzi tas-Sahha*

*Directorate of Healthcare Services*

**DH CIRCULAR No. 179/2014**

DH 1875/2014

8<sup>th</sup> May 2014

**Attention All:** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Re: Danaparoid Sodium 750units/0.6mL Injections**

It is being brought to your attention that following the discontinuation of lepirudin vials by the Marketing Authorisation Holder for commercial reasons, danaparoid sodium injections are available on the Government Formulary List as an alternative. Lepirudin was indicated for anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II and thromboembolic disease mandating parenteral antithrombotic therapy.

Danaparoid is for in-patient use and is regulated with protocol number 298 (attached). It can be prescribed by Consultant Haematologists, Consultant Surgeons in consultation with Consultant Haematologists, and Consultant Cardiologists in consultation with Consultant Haematologists.

For your attention please.

Dr. Denis Vella Baldacchino  
A/Director General Health Services

“PALAZZO CASTELLANIA” 15, MERCHANTS STREET, VALLETTA, VLT 2000

Tel. Nos. +00356 21224071/ 2299 2232

Fax no. +00356 2299 2663

e-mail: [cmo.mfh@gov.mt](mailto:cmo.mfh@gov.mt)

Version 04

Sep 12

**Danaparoid Sodium 750units/0.6mL Injections**

**Prescriber Criteria:** Consultant Surgeon in consultation with Consultant Haematologist  
Consultant Cardiologist in consultation with Consultant Haematologist  
Consultant Haematologist

**In-patient use:**

Heparin Induced Thrombocytopenia, for patients with platelet count of < 50% after heparin treatment.